Oral Microbiome Diagnostics of Lung Cancer - Trial NCT06270992
Access comprehensive clinical trial information for NCT06270992 through Pure Global AI's free database. This phase not specified trial is sponsored by TC Erciyes University and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 676 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
TC Erciyes University
Timeline & Enrollment
N/A
Nov 15, 2023
May 15, 2026
Primary Outcome
Diagnostics accuracy assessment
Summary
The study aims to develop a deep learning-based diagnostic method for lung cancer using the
 oral microbiome. This innovative approach involves establishing an observational cohort of
 576 individuals, including lung cancer patients, non-cancerous benign lung disease patients,
 and healthy controls, to collect tongue swab samples for 16S rRNA sequencing. Additionally,
 an international cohort of approximately 1700 individuals will be formed using in silico
 data. The project will utilize deep learning methods to analyze all data integratively and
 develop an AI diagnostic algorithm capable of distinguishing lung cancer patients from
 others. The diagnostic method's performance will be tested in a pilot clinical trial with 96
 individuals using a PRoBE design. Led by experts in chest surgery, molecular microbiology,
 and bioinformatics, the project spans over 30 months and aims to create a non-invasive,
 easily accessible lung cancer screening method that could lead to significant diagnostic
 advancements and potential spin-off companies in the field of liquid biopsy/molecular
 diagnosis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06270992
Non-Device Trial